Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients

B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the chemotherapy. To overcome these hurdles, novel therapies need to be investigated. One promis...

Descripción completa

Detalles Bibliográficos
Autores principales: Goroshchuk, Oksana, Vidarsdottir, Linda, Björklund, Ann-Charlotte, Hamil, Alexander S., Kolosenko, Iryna, Dowdy, Steven F., Palm-Apergi, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021816/
https://www.ncbi.nlm.nih.gov/pubmed/32060361
http://dx.doi.org/10.1038/s41598-020-59653-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021816/
https://www.ncbi.nlm.nih.gov/pubmed/32060361
http://dx.doi.org/10.1038/s41598-020-59653-5

Ejemplares similares